NexPoint Participates in Series C Financing for Apnimed, a Clinical-stage Pharmaceutical Company Focused on Treating Sleep Disorders
CAMBRIDGE, Mass. May 4, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that it has raised $62.5 million of committed capital in a Series C financing. New investor, Sectoral Asset Management, led the round. Also participating were new investors […]
NexPoint Managing Director Angela Barbera Receives Distinguished Service Award at ADISA 2021
Wrapping up a busy conference season in Q3, NexPoint attended ADISA’s annual conference at the Wynn in Las Vegas, Nevada where NexPoint Managing Director of National Accounts and Marketing and ADISA Board Member, Angela Barbera, was honored for her contributions and service to ADISA. Ms. Barbera is responsible for leading NexPoint’s marketing, national accounts, and […]
Dallas-Fort Worth Named a Top Market for Emerging Life Science
2021 brought a record-setting level of investment in life sciences with nearly $150 Billion of private and public funding, according to Cushman Wakefield and the National Institute of Health (NIH). 2021 brought a record-setting level of investment in life sciences with nearly $150 Billion of private and public funding, according to Cushman Wakefield and the […]
NexPoint Merger Arbitrage Fund Named Best Merger Arbitrage Fund at HFM U.S. Performance Awards
DALLAS, Nov. 11, 2020 — The NexPoint Merger Arbitrage Fund (the “Fund”) was recognized as the top fund in the Merger Arbitrage category at the HFM U.S. Performance Awards. Winners were announced on November 5, 2020, at a virtual awards program. The Fund was also recognized on the shortlist in two other categories: U.S. Equity Long-term Performance (5 […]
